GFAP and amyotrophic lateral sclerosis: Accordingly, plasma GFAP was significantly elevated in ALS patients displaying a full-blown FTD despite the lack of a significant difference in the biomarker levels across the Strong classification categories, probably due to the subgroups’ scarce numerosity.